EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Detecting ALK , ROS1 , and RET fusions and the METΔex14 splicing variant in liquid biopsies of non‐small‐cell lung cancer patients using RNA ‐based techniques

Ana Giménez-Capitán, Estela Sánchez-Herrero, Lucía Robado de Lope, Andrés Aguilar-Hernández, Ivana Sullivan, Virginia Calvo, Irene Moya-Horno, Santiago Viteri, Carlos Cabrera, Cristina Aguado, Noelia Armiger, Joselyn Valarezo und 6 weitere

Molecular Oncology · 2023

DOI: 10.1002/1878-0261.13468 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Ana Giménez-Capitán und 17 weiteren Autor:innen. Beteiligte Einrichtung: Pangaea Oncology, Laboratory of Oncology, Dexeus University Hospital, Barcelona, Spain. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Social Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ALK , ROS1 , and RET fusions and MET ∆ex14 variant associate with response to targeted therapies in non‐small‐cell lung cancer (NSCLC). Technologies for fusion testing in tissue must be adapted to liquid biopsies, which are often the only material available. In this study, circulating‐free RNA (cfRNA) and extracellular vesicle RNA (EV‐RNA) were purified from liquid biopsies. Fusion and MET ∆ex14 transcripts were analyzed by nCounter (Nanostring) and digital PCR (dPCR) using the QuantStudio ® System (Applied Biosystems). We found that nCounter detected ALK , ROS1 , RET , or MET ∆ex14 aberrant transcripts in 28/40 cfRNA samples from positive patients and 0/16 of control individuals (70% sensitivity). Regarding dPCR, aberrant transcripts were detected in the cfRNA of 25/40 positive patients. Concordance between the two techniques was 58%. Inferior results were obtained when analyzing EV‐RNA, where nCounter often failed due to a low amount of input RNA. Finally, results of dPCR testing in serial liquid biopsies of five patients correlated with response to targeted therapy. We conclude that nCounter can be used for multiplex detection of fusion and MET ∆ex14 transcripts in liquid biopsies, showing a performance comparable with next‐generation sequencing platforms. dPCR could be employed for disease follow‐up in patients with a known alteration. cfRNA should be preferred over EV‐RNA for these analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCell-Free Nucleic AcidsHumansProtein-Tyrosine KinasesAnaplastic Lymphoma KinaseRNAProto-Oncogene Proteins c-retProto-Oncogene ProteinsLiquid BiopsyOncogene Proteins, Fusion

Stichwörter der Autor:innen

digital PCRgene fusionsliquid biopsylung cancernCounter assaysplicing variants

Substanzen

Protein-Tyrosine KinasesAnaplastic Lymphoma KinaseRNAProto-Oncogene Proteins c-retProto-Oncogene ProteinsCell-Free Nucleic AcidsOncogene Proteins, FusionRET protein, humanROS1 protein, human

Autor:innen und Institutionen

  • Pangaea Oncology, Laboratory of Oncology, Dexeus University Hospital, Barcelona, Spain.
  • Atrys Health, Barcelona, Spain.
  • Liquid Biopsy Laboratory, Biomedical Sciences Research Institute Puerta de Hierro-Majadahonda, Madrid, Spain.
  • Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain.
  • Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Spain.

ORCID-Profile: Rafael Rosell, Atocha Romero, Miguel A Molina-Vila

Förderung

  • European Social Fund

Zitieren

APA

Giménez-Capitán, A., Sánchez-Herrero, E., Robado de Lope, L., Aguilar-Hernández, A., Sullivan, I., Calvo, V., Moya-Horno, I., Viteri, S., Cabrera, C., Aguado, C., Armiger, N., Valarezo, J., Mayo-de-Las-Casas, C., Reguart, N., Rosell, R., Provencio, M., Romero, A., & Molina-Vila, M. A. (2023). Detecting ALK , ROS1 , and RET fusions and the METΔex14 splicing variant in liquid biopsies of non‐small‐cell lung cancer patients using RNA ‐based techniques. Molecular Oncology. https://doi.org/10.1002/1878-0261.13468

Vancouver

Giménez-Capitán A, Sánchez-Herrero E, Robado de Lope L, Aguilar-Hernández A, Sullivan I, Calvo V, et al. Detecting ALK , ROS1 , and RET fusions and the METΔex14 splicing variant in liquid biopsies of non‐small‐cell lung cancer patients using RNA ‐based techniques. Molecular Oncology. 2023. doi:10.1002/1878-0261.13468

BibTeX
@article{GimnezCapitn2023,
  author = {Giménez-Capitán, Ana and Sánchez-Herrero, Estela and Robado de Lope, Lucía and Aguilar-Hernández, Andrés and Sullivan, Ivana and Calvo, Virginia and Moya-Horno, Irene and Viteri, Santiago and Cabrera, Carlos and Aguado, Cristina and Armiger, Noelia and Valarezo, Joselyn and Mayo-de-Las-Casas, Clara and Reguart, Noemí and Rosell, Rafael and Provencio, Mariano and Romero, Atocha and Molina-Vila, Miguel A},
  title = {Detecting ALK , ROS1 , and RET fusions and the METΔex14 splicing variant in liquid biopsies of non‐small‐cell lung cancer patients using RNA ‐based techniques},
  journal = {Molecular Oncology},
  year = {2023},
  doi = {10.1002/1878-0261.13468}
}
Kostenlos starten →